Nanobiotix is trading $36.50 (+5.71%) as investors react to final Phase 1 melanoma data presented at ESMO.
- The study reported a 41.7% response rate, including four complete responses, and median overall survival of 17.8 months.
- The preliminary data came from 24 heavily pre-treated patients; investigators called for randomized-trial evaluation.
- Results were announced October 24; no separate major company announcement was identified on October 27.